Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DISC-3405 in Healthy Volunteers
NCT06050915Phase 1Completed
- Sponsor
- Disc Medicine
- Start
- Oct 2023
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DISC-3405 in polycythemia vera (PV) (4 arms), sponsored by Disc Medicine. Primary endpoints: Incidence of adverse events up to 99 days, Incidence of treatment-emergent clinically abnormal physical exam up to 99 days and 3 more. Started Oct 2023; status: completed.
02
Drugs
DISC-3405
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on NCT06050915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06050915.